Objective: This study aims to assess the near equivalence of generic Lenvatinib to the patented Lenvatinib in patients with advanced hepatocellular carcinoma (HCC) in low- and middle-income countries (LMICs), with the goal of enhancing patient access and reducing financial burden, ultimately improving treatment adherence. Materials and Methods: This is a multi-centric retrospective cohort analysis of 2 cancer centres in Pakistan. Patients who received Lenvatinib between January 2023 and July 2024 for managing advanced HCC were enrolled. Inclusion criteria were radiologically confirmed advanced Hepatocellular Carcinoma, age > 18 years, ECOG status of 0-2, complete medical records. Patients were excluded if they had ECOG status of 3-4, Brain metastasis, pregnant/lactating females, or incomplete records. The primary endpoint was progression-free survival (PFS). The following factors were reviewed: ECOG, performance status, comorbidities, risk factors, etiology of cirrhosis, Child-Pugh score, prior treatment, and socioeconomic status. Tumour assessment was determined by reviewing radiology reports. Progression-free survival was determined by the Kaplan-Meier method. Confidence intervals were calculated where applicable, using SPSS version 26. Results: The study included 56 patients with a median age of 60 years. Chronic hepatitis C virus infection C (89.2%) was the predominant cause of liver disease, followed by chronic hepatitis B virus infection. 75% patients belonged to Child-Pugh class A at baseline. At baseline, tumor size > 5cm was present in 73.2% of patients, 14.3% had multifocal lesions, 44.6% had angioinvasion, and 23.2% had distant metastasis. 53.6% had received prior therapies, including trans-arterial chemoembolization (TACE) and or Sorafenib. 46.4% had not received any previous treatment. 83.9% received follow-up imaging at 4 months. The median number of cycles given was 5 and mPFS was 11.73 months (comparison is indirect and based on historical data such as the REFLECT trial). The response evaluation according to mRECIST criteria showed that 5.4% of patients achieved a complete response (CR), 19.6% had a partial response (PR), 23.2% experienced stable disease (SD), and 35.7% had progressive disease (PD). Additionally, 16.1% of patients did not complete their re-evaluation, with 14.3% primarily due to premature discontinuation of the drug due to toxicities such as diarrhea, hand foot syndrome (5.4%) and decompensation of liver disease (3.6%). Currently, 89.3% of patients are alive, 5.4% died, and the same ratio lost to follow-up Conclusions: The study demonstrated that generic Lenvatinib is an effective treatment option for advanced HCC in low- and middle-income countries (LMICs) patients, with a median progression-free survival (PFS) of 11.73 months (95% CI = 9.7,13.6), compared to 12.5 months. Keywords: Generic Lenvatinib; Hepatocellular; Carcinoma

References

1. Bray F., et al. “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries”. CA: A Cancer Journal Clinicians6 (2018): 394-424.
2. Joong-Won Park., et al. “Patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study”. Liver Interenational 35 (2015): 2155-2166.
3. Sulaiman Nanji., et al. “Confronting the challenges of hepatocellular carcinoma in sub-Saharan Africa: opportunities for progress”. JCO Global Oncology (2015).
4. John D Gordan., et al. “Systemic therapy for advanced Hepatocellular Carcinoma ASCO guidelines update”. Journal of Clinical Oncology (2024).  
5. Josep M Llovet., et al. “Sorafenib in advanced hepatocellular carcinoma”. New England Journal of Medicine 359 (2008): 378-390.
6. Yongsheng Pang., et al. “Adverse effects of sorafenib in hepatocellular carcinoma treatment”. American Journal of Cancer Research 6 (2022): 2770-2782.
7. Kudo M., et al. “Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial”. Lancet10126 (2018): 1163-1173.
8. Finn RS., et al. “Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma”. The New England Journal of Medicine20 (2020): 1894-1905.
9. Llovet JM., et al. “Sorafenib in advanced hepatocellular carcinoma”. The New England Journal of Medicine 4 (2008): 378-390.
10. Andrew Hill., et al. “Target prices for the mass production of tyrosine kinase inhibitors for global cancer treatment”. BMJ (2016).
11. Sulaiman Na. “Confronting the challenges of hepatocellular carcinoma in sub-Saharan Africa: opportunities for progress”. JCO Global Oncology 11 (2025): e2400645.
12. Butt AS. “Epidemiology of Viral Hepatitis and Liver Diseases in Pakistan”. Euroasian Journal of Hepato-Gastroenterology 1 (2015): 43-48.
13. Zaidi AA., et al. “The financial burden of cancer: Estimates from patients undergoing cancer care in a tertiary care hospital”. International Journal for Equity in Health 60 (2012).

Citation

Citation: Alishba Asif., et al. “Effectiveness of Generic Lenvatinib in Advanced Hepatocellular Carcinoma in Low and Middle-Income Countries".Acta Scientific Cancer Biology 9.3 (2025): 53-57.

Copyright

Copyright: © 2025 Alishba Asif., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.